RU2005140967A - METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF LOZARTAN AND RESVERATROL IN L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY - Google Patents
METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF LOZARTAN AND RESVERATROL IN L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY Download PDFInfo
- Publication number
- RU2005140967A RU2005140967A RU2005140967/14A RU2005140967A RU2005140967A RU 2005140967 A RU2005140967 A RU 2005140967A RU 2005140967/14 A RU2005140967/14 A RU 2005140967/14A RU 2005140967 A RU2005140967 A RU 2005140967A RU 2005140967 A RU2005140967 A RU 2005140967A
- Authority
- RU
- Russia
- Prior art keywords
- resveratrol
- endothelial dysfunction
- lozartan
- correction
- name
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2005140967/14A RU2306924C1 (en) | 2005-12-28 | 2005-12-28 | Method of correcting endothelial dysfunction with combination of lozartan and razveratrol in cases of loname-induced nitrogen monoxide deficiency |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2005140967/14A RU2306924C1 (en) | 2005-12-28 | 2005-12-28 | Method of correcting endothelial dysfunction with combination of lozartan and razveratrol in cases of loname-induced nitrogen monoxide deficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005140967A true RU2005140967A (en) | 2007-07-10 |
RU2306924C1 RU2306924C1 (en) | 2007-09-27 |
Family
ID=38316311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005140967/14A RU2306924C1 (en) | 2005-12-28 | 2005-12-28 | Method of correcting endothelial dysfunction with combination of lozartan and razveratrol in cases of loname-induced nitrogen monoxide deficiency |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2306924C1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2462765C1 (en) * | 2011-04-25 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for endothelial dysfunction correction by distant preconditioning in adma-like gestosis model |
RU2460148C1 (en) * | 2011-04-25 | 2012-08-27 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for placental microcirculation disorder correction in adma-like gestosis model |
RU2481103C1 (en) * | 2011-08-31 | 2013-05-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for placental microcirculation disorder correction in adma-like gestosis models in experiment by single ischemic episode |
RU2712102C1 (en) * | 2019-08-07 | 2020-01-24 | Федеральное государственное бюджетное учреждение науки Федеральный научный центр "Владикавказский научный центр Российской академии наук" (ВНЦ РАН) | Method for simulating endothelial dysfunction and pathology of internal organs in experiment |
-
2005
- 2005-12-28 RU RU2005140967/14A patent/RU2306924C1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2306924C1 (en) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2020038I1 (en) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
NL301037I2 (en) | Solamphetol or a pharmaceutically acceptable salt thereof, preferably the hydrochloride salt thereof | |
NO2012017I2 (en) | Azilsartan medoxomil and its pharmaceutically acceptable salt, including potassium salt | |
CL2007002640A1 (en) | COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER. | |
CL2007002642A1 (en) | COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER. | |
WO2007003962A3 (en) | Gpcr agonists | |
WO2007003961A3 (en) | Gpcr agonists | |
MY144857A (en) | Phamaceutical composition comprising amlodipine and losartan | |
BRPI0605921A2 (en) | organic compounds | |
AP2405A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms. | |
WO2008012622A3 (en) | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor | |
IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
GB2454620A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
EA201070786A1 (en) | BENZOFUROPYRIMIDINONES | |
NL1028193A1 (en) | Pharmaceutically active compounds. | |
WO2008044243A3 (en) | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof | |
Dawson | Functional occlusion | |
EP1861358A4 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same | |
EA201000039A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING SOLIFENACIN OR ITS PHARMACEUTICALLY ADAPTABLE SALT | |
EA201000439A1 (en) | Benzothiazols as modulators of the grelina receptor | |
RU2005140967A (en) | METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF LOZARTAN AND RESVERATROL IN L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | |
PT2366393E (en) | Roflumilast for the treatment of pulmonary hypertension | |
RU2005140968A (en) | METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF LOZARTAN AND L-ARGININE IN L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | |
WO2006106358A3 (en) | Use of nk-3 receptor antagonists for the treatment of nausea and vomiting | |
CL2004001507A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED ESPIROBENZOBENZAZEPINAS, VASOPRESINE RECEIVER INHIBITORS; PHARMACEUTICAL COMPOSITION; USEFUL IN THE TREATMENT OF HYPERTENSION, CARDIAC DYSFUNCTION, RENAL INSUFFICIENCY, AMONG OTHERS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20071229 |